Business Wire
BusinessDisney’s ABC takes on the FCC in a First Amendment lawsuit, after a judge pressed it to slow downThe Apex TimesBusinessFDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patientsThe Apex TimesBusinessAmazon shares jump after Evercore flags “agentic” AI as a potential retail growth leverThe Apex TimesBusinessJim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worriesThe Apex TimesBusinessAmerican Airlines to expand seatback screens and raise premium seating share to compete more closely with DeltaThe Apex TimesBusinessNvidia’s stock moves are diverging from the chip index, with correlation near zero, Yahoo Finance reportsThe Apex TimesBusinessApple TV Plus price rises again to $14.99 a month, following industry-wide subscription pushThe Apex TimesBusinessDevon Energy trades at a discount versus ConocoPhillips, but both banks on shale cash flow and shareholder returnsThe Apex TimesBusinessBank of America to Pay $72.5 Million to Resolve Epstein-Related Claims, With a Compliance Warning AttachedThe Apex TimesBusinessNovo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains centralThe Apex TimesBusinessPfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patientsThe Apex TimesBusinessAmazon Keeps Its Pricing Software “For Now” as Antitrust Case Heads Toward TrialThe Apex TimesBusinessDisney’s ABC takes on the FCC in a First Amendment lawsuit, after a judge pressed it to slow downThe Apex TimesBusinessFDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patientsThe Apex TimesBusinessAmazon shares jump after Evercore flags “agentic” AI as a potential retail growth leverThe Apex TimesBusinessJim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worriesThe Apex TimesBusinessAmerican Airlines to expand seatback screens and raise premium seating share to compete more closely with DeltaThe Apex TimesBusinessNvidia’s stock moves are diverging from the chip index, with correlation near zero, Yahoo Finance reportsThe Apex TimesBusinessApple TV Plus price rises again to $14.99 a month, following industry-wide subscription pushThe Apex TimesBusinessDevon Energy trades at a discount versus ConocoPhillips, but both banks on shale cash flow and shareholder returnsThe Apex TimesBusinessBank of America to Pay $72.5 Million to Resolve Epstein-Related Claims, With a Compliance Warning AttachedThe Apex TimesBusinessNovo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains centralThe Apex TimesBusinessPfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patientsThe Apex TimesBusinessAmazon Keeps Its Pricing Software “For Now” as Antitrust Case Heads Toward TrialThe Apex TimesBusinessDisney’s ABC takes on the FCC in a First Amendment lawsuit, after a judge pressed it to slow downThe Apex TimesBusinessFDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patientsThe Apex TimesBusinessAmazon shares jump after Evercore flags “agentic” AI as a potential retail growth leverThe Apex TimesBusinessJim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worriesThe Apex TimesBusinessAmerican Airlines to expand seatback screens and raise premium seating share to compete more closely with DeltaThe Apex TimesBusinessNvidia’s stock moves are diverging from the chip index, with correlation near zero, Yahoo Finance reportsThe Apex TimesBusinessApple TV Plus price rises again to $14.99 a month, following industry-wide subscription pushThe Apex TimesBusinessDevon Energy trades at a discount versus ConocoPhillips, but both banks on shale cash flow and shareholder returnsThe Apex TimesBusinessBank of America to Pay $72.5 Million to Resolve Epstein-Related Claims, With a Compliance Warning AttachedThe Apex TimesBusinessNovo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains centralThe Apex TimesBusinessPfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patientsThe Apex TimesBusinessAmazon Keeps Its Pricing Software “For Now” as Antitrust Case Heads Toward TrialThe Apex TimesBusinessDisney’s ABC takes on the FCC in a First Amendment lawsuit, after a judge pressed it to slow downThe Apex TimesBusinessFDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patientsThe Apex TimesBusinessAmazon shares jump after Evercore flags “agentic” AI as a potential retail growth leverThe Apex TimesBusinessJim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worriesThe Apex TimesBusinessAmerican Airlines to expand seatback screens and raise premium seating share to compete more closely with DeltaThe Apex TimesBusinessNvidia’s stock moves are diverging from the chip index, with correlation near zero, Yahoo Finance reportsThe Apex TimesBusinessApple TV Plus price rises again to $14.99 a month, following industry-wide subscription pushThe Apex TimesBusinessDevon Energy trades at a discount versus ConocoPhillips, but both banks on shale cash flow and shareholder returnsThe Apex TimesBusinessBank of America to Pay $72.5 Million to Resolve Epstein-Related Claims, With a Compliance Warning AttachedThe Apex TimesBusinessNovo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains centralThe Apex TimesBusinessPfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patientsThe Apex TimesBusinessAmazon Keeps Its Pricing Software “For Now” as Antitrust Case Heads Toward TrialThe Apex Times
Back to front
Lockheed Martin logs second successful flight test of its new JR3 rocket for lower-cost Army training
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 28, 1:17 PM EDT

Lockheed Martin logs second successful flight test of its new JR3 rocket for lower-cost Army training

The defense contractor says its Joint Reduced Range Rocket JR3 solution, using a reusable launch pod, demonstrated range, trajectory, accuracy and marking effects in a Yuma Proving Ground test and is intended to replace the Army’s current reduced-range practice round.

3 min readEditor-approved Apex article

Lockheed Martin said it has conducted the second successful test of its Joint Reduced Range Rocket, or JR3, a lower-cost training round designed to support U.S. Army readiness and help enable training with global partners. The company framed JR3 as a replacement for the Army’s current Reduced Range Practice Rocket, aiming to improve affordability while preserving the ability to evaluate performance in realistic training conditions.

In the test, conducted at Yuma Proving Ground in Arizona, Lockheed Martin launched multiple training rounds and reported success across several categories, including range, trajectory, accuracy and “marking payload effects.” Those elements speak to both how far the round travels and how precisely it follows a planned flight path, as well as whether it produces observable end-of-flight effects used during training.

JR3 is described by Lockheed Martin as an “affordable training round” that pairs with a reusable launch pod. Reusability is intended to reduce recurring costs associated with training munitions, which can be a major driver of budgets for large-scale force readiness activities, particularly when live rounds are used for recurring exercises.

The company’s release did not provide additional test numbers such as the number of rounds fired in the second campaign, pass or fail criteria, or performance margins for accuracy. It also did not disclose what specific marking effects were demonstrated beyond noting that payload effects were observed and evaluated during the flights.

Lockheed Martin said the JR3 effort is aligned with what it calls all-domain deterrence and “the future needs of those who serve,” placing the program within a broader narrative about delivering capabilities for training and readiness. The release included language about the company’s “21st Century Security” vision, but it did not tie JR3 to a specific procurement milestone, contract value, or fielding schedule.

The use of reduced-range munitions is intended to let forces conduct training without employing full-range or operational munitions. In that context, JR3’s stated goal of replacing the current Reduced Range Practice Rocket points to a potential modernization of the Army’s training ammunition set, which can influence how often training ranges can be used and how quickly units can cycle through repeated exercises.

For Lockheed Martin, JR3 also represents a continuation of its role in missile and rocket-related defense work, where training systems can create steady demand alongside weapons used for operational missions. While the release does not quantify potential customers or timelines, it describes JR3 as relevant not only to the U.S. Army but also to “global partners,” suggesting the solution could be positioned for allied and partner training needs.

What remains unclear from the announcement is whether JR3 has reached any formal qualification status, whether the second test follows a prior test campaign with comparable objectives, or when the Army expects to evaluate the system for broader use. The company also did not provide details about how the reusable launch pod will be serviced, how often it can be reused, or what cost targets the design aims to achieve.

Next, the practical question for observers is what comes after flight testing: whether additional rounds or test phases are planned, and whether any public procurement or qualification updates follow. For units focused on readiness, the near-term impact will depend on how quickly reduced-range training options can be evaluated and integrated into training cycles at ranges like Yuma Proving Ground.

Why It Matters

  • Lower-cost training rounds can affect how frequently and at what scale units are able to practice, which can influence readiness planning.
  • If JR3 replaces the current reduced-range practice option, it could modernize how the Army and partners conduct live-fire training on restricted or reduced-range schedules.
  • Demonstrating range, trajectory, accuracy, and observable marking effects addresses key training needs, not just launch mechanics.
  • For Lockheed Martin, successful test milestones in training ammunition can support future qualification and customer evaluation efforts.

Sources

Key Facts

  • Lockheed Martin said it successfully conducted a second flight test of its Joint Reduced Range Rocket (JR3) training solution.
  • The test took place at Yuma Proving Ground, Arizona, and included multiple training round launches.
  • Lockheed Martin reported successful demonstrations of range, trajectory, accuracy, and marking payload effects.
  • JR3 is described as an affordable training round intended to replace the U.S. Army’s current Reduced Range Practice Rocket.
  • The solution includes a reusable launch pod, designed to reduce the cost of repeated training.

Defense Related

Lockheed Martin logs second successful flight test of its new JR3 rocket for lower-cost Army training | The Apex Times